MedTrace Logo

Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV Reactivation

NCT01326273 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2015-06-08

No results posted yet for this study

Summary

The investigators will assess whether the infusion of autologous CMV-specific T-cells at the time of CMV reactivation posttransplant will prevent worsening of CMV virus reactivation posttransplant to a level that warrants therapy with antiviral drugs (objectively assessed by looking at CMV virus copy number).

Conditions

  • CMV Reactivation
  • Allogeneic Stem Cell Transplantation
  • Autologous CMV Specific CD8+ T Cells

Interventions

PROCEDURE

Lymphopheresis

Lymphopheresis

PROCEDURE

CMV specific lymphocyte infusion

CMV specific lymphocyte infusion

PROCEDURE

Peripheral blood for CMV DNA PCR

Peripheral blood for CMV DNA PCR

PROCEDURE

Haematology/Blood chemistry

Haematology/Blood chemistry analysis, Collection of blood for ancillary laboratory tests.

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Katy Rezvani, MD · Imperial College Healthcare NHS Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01326273 on ClinicalTrials.gov